Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$770.00 USD

770.00
1,669,052

-1.12 (-0.15%)

Updated May 17, 2024 04:00 PM ET

After-Market: $770.30 +0.30 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (190 out of 249)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN

How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?

    Arpita Dutt headshot

    Drug Stocks Rally on Trump Meet with Pharma Bigwigs

    Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.

      Ryan McQueeney headshot

      Biotech Stocks Gain on Latest Trump Drug Price Statements

      President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

        Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues

        Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.

          Incyte and Calithera Enter into Deal for Oncology Candidate

          Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

            Lilly (LLY) Q4 Earnings Miss, Revenues Beat

            Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.

              Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?

              Eli Lilly (LLY) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

                Arpita Dutt headshot

                Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

                2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                  Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE

                  Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.

                    Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?

                    We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.

                      Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                      We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.

                        Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug

                        Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).

                          Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?

                          We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.

                            The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical

                            The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical

                              Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

                              AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

                                Mark Vickery headshot

                                Top Research Reports for January 24, 2017

                                Today's Research Daily features new research reports on 16 major stocks, including American Express (AXP), Time Warner (TWX), and Eli Lilly (LLY).

                                  What's in Store for Abbott Labs (ABT) This Earnings Season?

                                  Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

                                    Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

                                    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

                                      4 Drug Stocks Poised to Surprise this Earnings Season

                                      Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.

                                        Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

                                        Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

                                          Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

                                          Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.

                                            Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

                                            Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

                                              Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

                                              Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

                                                Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

                                                We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

                                                  What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

                                                  Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.